RxDoctor Payments Data

Meredith Rubado

Family · Alexandria Bay, NYNPI 1114377413

Payments from drug & device makers

$539in general payments, 2019–2025

Across 27 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hydrofera LLC$103
  • AbbVie$100
  • Abbott$56
  • Novo Nordisk$51
  • AstraZeneca$48
  • Exact Sciences$37
  • plus $144 from 8 others

What the payments were for

  • Food & beverage$539100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$539 in reported general payments places this provider in the 60th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$3,388
Medicare patients
23
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol44$59,755
OzempicSemaglutide54$58,552
TrulicityDulaglutide32$48,010
JanuviaSitagliptin Phosphate25$36,745
XareltoRivaroxaban20$24,116
EliquisApixaban17$20,621
Nurtec OdtRimegepant Sulfate11$20,201
JardianceEmpagliflozin12$20,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,383
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,607
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$3,486
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,257
Albuterol Sulfate HfaAlbuterol Sulfate66$2,741
Gabapentin103$1,618
Duloxetine Hcl24$1,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$48$59,75544 claims
Novo NordiskOzempic$51$58,55254 claims
Lilly USA, LLCTrulicity$29$48,01032 claims
MerckJanuvia$26$36,74525 claims
Boehringer IngelheimJardiance$19$20,01512 claims
GSKTrelegy Ellipta$14$13,38314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,883 family providers in New York.

Other family in Alexandria Bay

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →